Elitek® Rasburicase 1.5 mg Injection for Tumor Lysis Syndrome - 3 Vial Pack
USAMP#40462043SKU: 00024515010Elitek®
License Required
Product Spotlight
- Elitek® Rasburicase is a critical therapy for managing elevated plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies undergoing anticancer therapy, which may lead to tumor lysis syndrome.
- Formulated for both pediatric and adult patients, Elitek is recommended for a single treatment course to prevent acute uric acid nephropathy.
- Each package includes three single-use vials of 1.5 mg rasburicase, accompanied by three 1 mL diluent ampules, ensuring precise and safe administration.
